PASITHEA THERAPEUTICS CORP. Other Income and Expense
PASITHEA THERAPEUTICS CORP. (KTTA) reported Other Income and Expense of $439.43 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Income Statement › Other Income
us-gaap:NonoperatingIncomeExpense · last filed 2026-08-14
- PASITHEA THERAPEUTICS CORP. nonoperating income (expense) for the quarter ending 2026-06-30 was $439.43K, a 363.82% increase year-over-year.
- PASITHEA THERAPEUTICS CORP. nonoperating income (expense) for the quarter ending 2026-03-31 was $2.01M, a 1616.39% increase year-over-year.
- PASITHEA THERAPEUTICS CORP. nonoperating income (expense) for the quarter ending 2025-12-31 was $145.29K, a 77.43% increase year-over-year.
- PASITHEA THERAPEUTICS CORP. nonoperating income (expense) for the quarter ending 2025-09-30 was $72.64K, a 1422.75% increase year-over-year.
- PASITHEA THERAPEUTICS CORP. nonoperating income (expense) for fiscal 2025 was $429.61K, a 24.39% increase from fiscal 2024.
- PASITHEA THERAPEUTICS CORP. nonoperating income (expense) for fiscal 2024 was $345.38K, a 26.77% decline from fiscal 2023.
- PASITHEA THERAPEUTICS CORP. nonoperating income (expense) for fiscal 2023 was $471.61K.
- PASITHEA THERAPEUTICS CORP. nonoperating income (expense) for fiscal 2021 was $2.33M.
| Period end | Nonoperating Income (Expense) 3 month | Nonoperating Income (Expense) 6 month | Nonoperating Income (Expense) 9 month | Nonoperating Income (Expense) 12 month |
|---|---|---|---|---|
| 2026-06-30 | $439.43K 10-Q · filed 2026-08-14 | $2.45M 10-Q · filed 2026-08-14 | $2.59M derived: sum of 3 quarters · filed 2026-08-14 | $2.66M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $2.01M 10-Q · filed 2026-05-15 | $2.15M derived: sum of 2 quarters · filed 2026-05-15 | $2.23M derived: sum of 3 quarters · filed 2026-05-15 | $2.32M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $145.29K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $217.93K derived: sum of 2 quarters · filed 2026-03-30 | $312.67K derived: sum of 3 quarters · filed 2026-08-14 | $429.61K 10-K · filed 2026-03-30 |
| 2025-09-30 | $72.64K 10-Q · filed 2025-11-13 | $167.38K derived: sum of 2 quarters · filed 2026-08-14 | $284.32K 10-Q · filed 2025-11-13 | $366.21K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $94.74K 10-Q · filed 2026-08-14 | $211.68K 10-Q · filed 2026-08-14 | $293.57K derived: sum of 3 quarters · filed 2026-08-14 | $298.34K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $116.94K 10-Q · filed 2026-05-15 | $198.83K derived: sum of 2 quarters · filed 2026-05-15 | $203.60K derived: sum of 3 quarters · filed 2026-05-15 | $282.38K derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $81.89K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $86.66K derived: sum of 2 quarters · filed 2026-03-30 | $165.44K derived: sum of 3 quarters · filed 2026-03-30 | $345.38K 10-K · filed 2026-03-30 |
| 2024-09-30 | $4.77K 10-Q · filed 2025-11-13 | $83.56K derived: sum of 2 quarters · filed 2025-11-13 | $263.49K 10-Q · filed 2025-11-13 | $381.01K derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $78.78K 10-Q · filed 2025-08-14 | $258.72K 10-Q · filed 2025-08-14 | $376.24K derived: sum of 3 quarters · filed 2025-08-14 | $552.97K derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $179.93K 10-Q · filed 2025-05-15 | $297.45K derived: sum of 2 quarters · filed 2025-05-15 | $474.19K derived: sum of 3 quarters · filed 2025-05-15 | $704.80K derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $117.52K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | $294.25K derived: sum of 2 quarters · filed 2025-03-24 | $524.87K derived: sum of 3 quarters · filed 2025-03-24 | $471.61K 10-K · filed 2025-03-24 |
| 2023-09-30 | $176.74K 10-Q · filed 2024-11-13 | $407.35K derived: sum of 2 quarters · filed 2024-11-13 | $354.10K 10-Q · filed 2024-11-13 | |
| 2023-06-30 | $230.62K 10-Q · filed 2024-08-13 | $177.36K 10-Q · filed 2024-08-13 | ||
| 2023-03-31 | -$53.26K 10-Q · filed 2024-05-14 | |||
| 2022-09-30 | -$335.32K 10-Q · filed 2022-11-14 | $86.38K derived: sum of 2 quarters · filed 2022-11-14 | $916.68K 10-Q · filed 2022-11-14 | $3.50M derived: sum of 4 quarters · filed 2022-11-14 |
| 2022-06-30 | $421.70K 10-Q · filed 2022-08-15 | $1.25M 10-Q · filed 2022-08-15 | $3.84M derived: sum of 3 quarters · filed 2022-08-15 | $3.59M derived: sum of 4 quarters · filed 2022-11-14 |
| 2022-03-31 | $830.30K 10-Q · filed 2022-05-16 | $3.42M derived: sum of 2 quarters · filed 2022-05-16 | $3.16M derived: sum of 3 quarters · filed 2022-11-14 | |
| 2021-12-31 | $2.59M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | $2.33M derived: sum of 2 quarters · filed 2022-11-14 | $2.33M 10-K · filed 2022-03-30 | |
| 2021-09-30 | -$252.51K 10-Q · filed 2022-11-14 | -$252.51K 10-Q · filed 2022-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Rocket One Inc. (RKTO) | United States | $0.019B |